Mechanisms of resistance to immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors ('targeted therapies'...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	British journal of cancer Ročník 118; číslo 1; s. 9
Hlavní autori:	Jenkins, Russell W, Barbie, David A, Flaherty, Keith T
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Nature Publishing Group 01.01.2018
Predmet:	Animals Biomarkers Cancer Chemotherapy CTLA-4 protein Cytotoxicity Drug Resistance, Neoplasm Humans Immune checkpoint inhibitors Immune response Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Immunotherapy Lymphocytes T Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - immunology PD-1 protein PD-L1 protein Signal Transduction - drug effects T-Lymphocytes - drug effects Tumors
ISSN:	0007-0920, 1532-1827, 1532-1827
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!